How Varenicline Works: Identifying Critical Receptor and Ligand-based Interactions

Abstract

Approved by the FDA in 2006, varenicline became the first nicotinic-based therapeutic for smoking cessation and has since been used by tens of millions of smokers worldwide. Varenicline works by targeting the 4{beta}2 nicotinic acetylcholine receptor (nAChR), the primary focus for nicotine addiction, where ligand recognition by the receptor triggers ion channel opening. While widely recognized that vareniclines development was rooted in the well-established pharmacology of cytisine, the two compounds display notably different profiles, not only at nAChRs, but also at key off-target sites such as the 5-HT3 serotonin receptor. Despite vareniclines widespread use and proven efficacy as a smoking cessation aid, our knowledge of the precise molecular mechanism underlying its action, particularly the specific receptor-ligand interactions that underpin its functional specificity, remains incomplete. Through a multidisciplinary approach that integrates complementary fields of research, this study reveals the critical receptor-ligand interactions that distinguish varenicline from related nAChR agonists, such as cytisine and nicotine. Our findings reveal previously unrecognized, critical hydrogen bonding interactions within the 4{beta}2 binding sites, specifically involving 4T139, 4T183, and {beta}2S133, that are uniquely and selectively engaged by varenicline. Of these, {beta}2S133 emerged as the pivotal determinant of vareniclines function, with substitution by valine significantly impairing the ligand efficacy. Furthermore, the design and synthesis of novel varenicline analogues shed new light into the functional importance of the ligands quinoxaline moiety, revealing that not just the presence but also the precise positioning of this hydrogen bond acceptor are critical for receptor activation by varenicline. Together, these findings uncover a previously uncharacterized interaction network essential for vareniclines function at 4{beta}2, offering a deeper and more comprehensive framework for understanding its distinct pharmacological profile while expanding our broader understanding of how ligand binding is translated into function in these receptors. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=174 SRC="FIGDIR/small/659675v1_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@a77e39org.highwire.dtl.DTLVardef@4fec37org.highwire.dtl.DTLVardef@11d26a2org.highwire.dtl.DTLVardef@d35640_HPS_FORMAT_FIGEXP M_FIG C_FIG